ALLK:NSD-Allakos Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.02

Change

0.00 (0.00)%

Market Cap

USD 0.17B

Volume

0.65M

Avg Analyst Target

USD 6.50 (+115.23%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ALLK Stock Forecast & Price:
Based on the Allakos Inc stock forecasts from 3 analysts, the average analyst target price for Allakos Inc is USD 6.50 over the next 12 months. Allakos Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Allakos Inc is Slightly Bearish, which is based on 2 positive signals and 3 negative signals. At the last closing, Allakos Inc’s stock price was USD 3.02. Allakos Inc’s stock price has changed by -9.58% over the past week, +2.03% over the past month and -96.48% over the last year.

About Allakos Inc (ALLK:NSD)

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is i ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-07-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

N/A

USD73.48B 29.71 20.69
REGN Regeneron Pharmaceuticals Inc

N/A

USD65.40B 8.39 6.52
MRNA Moderna Inc

N/A

USD59.64B 4.20 2.94
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

USD38.28B 2.86 1.54
SGEN Seagen Inc

N/A

USD33.15B 55.02 -50.53
RPRX Royalty Pharma Plc

N/A

USD28.81B 29.89 16.26
GMAB Genmab AS

N/A

USD21.88B 64.29 5.76
ARGX argenx NV ADR

N/A

USD20.61B N/A -30.89
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ALLK

Symbol Name Weight Mer Price(Change) Market Cap
PQSG PGIM ETF Trust - PGIM QMA.. 0.00 % 0.29 %

N/A

USD0.01B
IBBJ Defiance Nasdaq Junior Bi.. 0.00 % 0.45 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -69.15% 18% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -69.15% 18% F 14% F
Trailing 12 Months  
Capital Gain -96.48% 1% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -96.48% 1% F 1% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 17.89% 68% D+ 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.89% 67% D+ 74% C
Risk Return Profile  
Volatility (Standard Deviation) 60.63% 46% F 23% F
Risk Adjusted Return 29.51% 73% C 61% D-
Market Capitalization 0.17B 56% F 37% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.68 83% B 88% B+
Price / Cash Flow Ratio -0.80 22% F 55% F
EV/EBITDA 0.05 34% F 56% F
Management Effectiveness  
Return on Equity -93.92% 30% F 13% F
Return on Invested Capital -49.36% 54% F 20% F
Return on Assets -49.97% 15% F 5% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 4.52 52% F 38% F
Short Percent 11.17% 19% F 16% F
Beta 0.96 72% C- 61% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector